Efficacy of probiotics in multiple sclerosis: a systematic review of preclinical trials and meta-analysis of randomized controlled trials
The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
Abstract
= 0%; 95% CI, -1.12 to -0.33; P = 0.0003), with very low certainty of evidence. In addition, probiotic intake markedly improved insulin resistance and inflammatory and oxidative stress markers. Preclinical studies have shown that probiotic consumption reduces the incidence and severity of MS, delays MS progression (15 studies), and improves motor impairment (3 studies) with favorable alterations of immune and inflammatory markers (20 studies) and intestinal microbiome compositions (4 studies) in MS. These results indicated that probiotics may have beneficial effects on the prevention and treatment of multiple sclerosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therefore, modulation of the microbiota-gut-brain axis using probiotics could be a promising complementary approach to traditional methods to prevent or counteract these disorders, including PD, as widely reported in literature [315,317,318,319,320].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [317]
Citations
Cites
2 retracted
Kouchaki, E., Tamtaji, O. R., Salami, M., Bahmani, F., Daneshvar Kakhaki, R., Akbari, E., Tajabadi-Ebrahimi, M., Jafari, P., & Asemi, Z. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.08.015 · Cited by 317
RetractedTamtaji, O. R., Kouchaki, E., Salami, M., Aghadavod, E., Akbari, E., Tajabadi-Ebrahimi, M., & Asemi, Z. (2017) · Journal of the American College of Nutrition · doi:10.1080/07315724.2017.1347074 · Cited by 116
RetractedThe Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
SYRCLE’s risk of bias tool for animal studies
Hooijmans, C. R., Rovers, M. M., de Vries, R. B., Leenaars, M., Ritskes-Hoitinga, M., & Langendam, M. W. (2014) · BMC Medical Research Methodology · doi:10.1186/1471-2288-14-43 · Cited by 4,415
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357
The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication
Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00025 · Cited by 3,043
Alterations of the human gut microbiome in multiple sclerosis
Jangi, S., Gandhi, R., Cox, L. M., Li, N., von Glehn, F., Yan, R., Patel, B., Mazzola, M. A., Liu, S., Glanz, B. L., et al. (2016) · Nature Communications · doi:10.1038/ncomms12015 · Cited by 1,307
The prevalence of MS in the United States: A population-based estimate using health claims data
Wallin, M. T., Culpepper, W. J., Campbell, J. D., Nelson, L. M., Langer-Gould, A., Marrie, R. A., Cutter, G. R., Kaye, W. E., Wagner, L., Tremlett, H., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007035 · Cited by 1,098
The gut microbiota at the intersection of diet and human health
Gentile, C. L., & Weir, T. L. (2018) · Science · doi:10.1126/science.aau5812 · Cited by 1,049
Cekanaviciute, E., Yoo, B. B., Runia, T. F., Debelius, J. W., Singh, S., Nelson, C. A., Kanner, R., Bencosme, Y., Lee, Y. K., Hauser, S. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711235114 · Cited by 1,036
Research works printed but not linked: 7
- Correale, 2017, Brain, 140, 527
- Filippini, 2017, Cochrane Database Syst. Rev., 4, Cd012200
- Hashemi, 2018, Neurol.: Genet., 4, e278
- Goudarzvand, 2016, Med. J. Islam. Repub. Iran, 30, 391
- Ebrahim, 2017, Clin. Nutr., 36, 1245, 10.1016/j.clnu.2016.08.015 · DOI · Paper page
- Ochoa-Repáraz, 2010, J. Immunol., 185, 4101, 10.4049/jimmunol.1001443 · DOI · Paper page
- Samani, 2020, Basic Clin. Neurosci., 5, 1396
Cited by
Microbial dysbiosis in the gut drives systemic autoimmune diseases
Mousa, W. K., Chehadeh, F., & Husband, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.906258 · Cited by 185
Bicknell, B. T., Liebert, A. D., Borody, T. J., Herkes, G., McLachlan, C. S., & Kiat, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119577 · Cited by 147
“Probiotic studies have shown substantial improvements in multiple animal models of neurodegenerative [231,369–373] and neurodevelopmental diseases [374,375], PD [371,376], and cognitive decline [377] and reductions in symptoms in MS [378], ALS [379], and ASD [380].”
Varesi, A., Campagnoli, L. I. M., Fahmideh, F., Pierella, E., Romeo, M., Ricevuti, G., Nicoletta, M., Chirumbolo, S., & Pascale, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012289 · Cited by 88
Snetselaar, L., Cheek, J. J., Fox, S. S., Healy, H. S., Schweizer, M. L., Bao, W., Kamholz, J. A., & Titcomb, T. J. (2022) · Neurology · doi:10.1212/wnl.0000000000201371 · Cited by 94
“Unauthorized reproduction of this article is prohibited. reduce fatigue and improve physical and mental QoL among people with MS.”
BackgroundInfluentialChu, C., Yu, L., Li, Y. H., Guo, H., Zhai, Q., Chen, W., & Tian, F. (2023) · Nutrients · doi:10.3390/nu15071737 · Cited by 79
Chen, X., Hu, Y., Yuan, X., Yang, J., & Li, K. (2021) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00986-3 · Cited by 57
“At present, the application of probiotics in multiple sclerosis, inflammatory bowel disease, severe head injury and other diseases has achieved good clinical results [12, 13, 50, 51].”
BackgroundImpact of Microbiome–Brain Communication on Neuroinflammation and Neurodegeneration
Stolzer, I., Scherer, E., Süß, P., Rothhammer, V., Winner, B., Neurath, M. F., & Günther, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914925 · Cited by 50
“Strategies such as probiotics, prebiotics, and fecal microbiota transplantation have shown promise in preclinical studies and are currently being investigated in clinical trials [170,171].”
Hashemi, B., Abdollahi, M., Abbaspour‐Aghdam, S., Hazrati, A., Malekpour, K., Meshgi, S., Kafil, H. S., Ghazi, F., Yousefi, M., Roshangar, L., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114195 · Cited by 52
Feeding the gut microbiome: impact on multiple sclerosis
Bronzini, M., Maglione, A., Rosso, R., Matta, M., Masuzzo, F., Rolla, S., & Clerico, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1176016 · Cited by 54
The Brain–Gut–Bone Axis in Neurodegenerative Diseases: Insights, Challenges, and Future Prospects
Li, R., Miao, Z., Liu, Y., Chen, X., Wang, H., Su, J., & Chen, J. (2024) · Advanced Science · doi:10.1002/advs.202307971 · Cited by 65
Blais, L. L., Montgomery, T. L., Amiel, E., Deming, P. B., & Krementsov, D. N. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1943289 · Cited by 49
“12,26–34 To date, there have been two published reviews that evaluate the clinical utility of probiotics and explore possible underlying mechanisms, including one systematic review of two clinical and five preclinical studies,(31) and one recent study with a meta-analysis of three clinical studies and systematic revie…”
BackgroundFaghfouri, A. H., Afrakoti, L. G. M. P., Kavyani, Z., Nogourani, Z. S., Musazadeh, V., Jafarlou, M., & Dehghan, P. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01332-8 · Cited by 49
“The included studies had been conducted in China (Chan et al. 2021; Chen et al. 2020; Dai et al. 2022; Den et al. 2020; Jia et al. 2018; Jiang et al. 2021; Li et al. 2022; Liu et al. 2021; Ma et al. 2013; Mazidi et al. 2017; Pan et al. 2017; Tang et al. 2019; Wang et al. 2021; Xiao et al 2019; Yao…”
Targeting gut microbiota: new therapeutic opportunities in multiple sclerosis
Kujawa, D., Łaczmański, Ł., Budrewicz, S. P., Pokryszko‐Dragan, A., & Podbielska, M. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2274126 · Cited by 47
Convergent pathways of the gut microbiota–brain axis and neurodegenerative disorders
Gubert, C., Gasparotto, J., & Morais, L. H. (2022) · Gastroenterology report · doi:10.1093/gastro/goac017 · Cited by 45
“They performed a systematic review of 22 preclinical studies revealing positive effects of probiotics in the progression of MS, including decreasing incidence, and ameliorating the severity of the disease and motor impairment [233].”
Musazadeh, V., Faghfouri, A. H., Zarezadeh, M., Pakmehr, A., Moghaddam, P. T., Hamedi, F., Jahandideh, A., & Ghoreishi, Z. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1117387 · Cited by 39
“(33) Yes Partial Yes Yes Partial Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes High”
BackgroundChu, C., Li, T., Yu, L., Li, Y. H., Li, M., Guo, M., Zhao, J., Zhai, Q., Tian, F., & Chen, W. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c07606 · Cited by 39
Aznar, M. D. G., Guerrero, M. D. V., Ramos, J., Madueño, S. E., Bravo, M. M., Ruiz, R. L., & García, M. B. (2022) · BMC Neurology · doi:10.1186/s12883-022-02913-w · Cited by 36
“Probiotic intake markedly improved insulin resistance and inflammatory and oxidative stress markers [47].”
BackgroundMirashrafi, S., Taghanaki, S. Z. H., Sarlak, F., Moravejolahkami, A. R., Kermani, M. A. H., & Haratian, M. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.14724 · Cited by 34
Game of microbes: the battle within – gut microbiota and multiple sclerosis
Turner, T.-A. J., Lehman, P., Ghimire, S., Shahi, S. K., & Mangalam, A. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2387794 · Cited by 36
Melamed, E., Palmer, J. L., & Fonken, C. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1019877 · Cited by 30
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Fernández, Ó., Sørensen, P. S., Comı, G., Vermersch, P., Hartung, H., Leocani, L., Berger, T., Wijmeersch, B. V., & Oreja‐Guevara, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1379538 · Cited by 43
Gill Jenkins, P. M. (2022) · Food & Nutrition Journal · doi:10.29011/2575-7091.100245 · Cited by 45
“Other promising areas of research related to probiotic supplementation and conditions of the nervous system include Parkinson’s disease [106] and multiple sclerosis [107].”
Gastrointestinal Microbiome and Multiple Health Outcomes: Umbrella Review
Chang, C., Yuan, X., Zhang, X., Chen, X., & Li, K. (2022) · Nutrients · doi:10.3390/nu14183726 · Cited by 24
A review of the auditory-gut-brain axis
Graham, A. S., Ben‐Azu, B., Tremblay, M., Torre, P., Senekal, M., Laughton, B., van der Kouwe, A. J. W., Jankiewicz, M., Kaba, M., & Holmes, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1183694 · Cited by 23
Zangeneh, Z., Rostamian, M., Motamedi, H., Alvandi, A., & Abiri, R. (2025) · PLoS ONE · doi:10.1371/journal.pone.0319755 · Cited by 20
“Although the pathogenesis of MS is multifactorial, it seems that inflammation and oxidative stress factors (OSF) are important causes of MS, and we believe that the severity of MS (according to the EDSS criteria) is directly related to the level of inflammation and OSFs [3,4].”
Ibrahim, H.-I. M., Sheikh, A., Khalil, H. E., & Khalifa, A. Y. Z. (2023) · Nutrients · doi:10.3390/nu15030550 · Cited by 17
“Preclinical studies have shown that probiotic consumption reduces the incidence and severity of MS [24].”
BackgroundProbiotics/prebiotics/synbiotics and human neuropsychiatric outcomes: an umbrella review
Du, Q., Li, Q., Liu, C., Liao, G., Li, J., Yang, J., Zhang, Q., Gong, X., & Li, K. (2017) · Beneficial Microbes · doi:10.1163/18762891-bja00035 · Cited by 21
Zhu, F., Yin, S., Wang, Y., Zhong, Y., Ji, Q., & Wu, J. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s499406 · Cited by 11
Liang, S., Wang, L., Wu, X., Hu, X., Wang, T., & Jin, F. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2022.957688 · Cited by 14
Khalifa, A. Y. Z., Ibrahim, H.-I. M., Sheikh, A., & Khalil, H. E. (2023) · Pharmaceuticals · doi:10.3390/ph16030357 · Cited by 12
Unveiling the Important Role of Gut Microbiota and Diet in Multiple Sclerosis
Džidić-Krivić, A., Begagić, E., Hadžić, S., Bećirović, A., Bečirović, E., Hibić, H., Lihić, L. T., Vukas, S. K., Bečulić, H., Kasapović, T., et al. (2025) · Brain Sciences · doi:10.3390/brainsci15030253 · Cited by 15
“Clinical trials have also shown that administering probiotics, like capsules containing Lactobacillus and Bifidobacterium strains, resulted in improvements in disability, depression, and overall health, along with reduced expression of pro-inflammatory cytokines [89,159,160].”
Sharma, T., Mehan, S., Tiwari, A., Khan, Z., Gupta, G. D., & Narula, A. S. (2024) · Current Neurovascular Research · doi:10.2174/0115672026336440240822063430 · Cited by 10
Sjögren’s Syndrome Treatments in the Microbiome Era
Freguia, C. F., Pascual, D. W., & Fanger, G. R. (2023) · Advances in Geriatric Medicine and Research · doi:10.20900/agmr20230004 · Cited by 11
“Preliminary evidence shows the potential role of probiotics in ameliorating multiple sclerosis (MS), and MS patients receiving probiotics revealed significant beneficial effects of probiotic supplementation on their mental health [95,96].”
BackgroundProbiotic Influences on Motor Skills: A Review
Lalonde, R., & Strazielle, C. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230807150523 · Cited by 6
“Meta-analyses revealed the beneficial effects of probiotic supplementation on general health and depression in patients with multiple sclerosis [50-52].”
BackgroundLi, Q., Wang, G., Zhao, J., Chen, W., & Tian, P. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128286 · Cited by 7
Naseri, A., Sanaie, S., Rahnemayan, S., Mosaddeghi-Heris, R., Talebi, M., & Talebi, M. (2025) · Pharmaceutical Sciences · doi:10.34172/ps.025.41013 · Cited by 7
Kumar, N., Tyagi, N., Mehan, S., & Singh, A. P. (2024) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273336107241015100912 · Cited by 8
Eghbal, Y., & Naseri, A. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107264 · Cited by 3
Causal effects of gut microbiota on multiple sclerosis: A two‐sample Mendelian randomization study
Sun, D., Zhang, Y., Wang, R., Du, Q., Shi, Z., Chen, H., Wang, X., & Zhou, H. (2024) · Brain and Behavior · doi:10.1002/brb3.3593 · Cited by 4
Wang, Y., Yan, W., Yao, L., Liu, W., Yin, Z., Xiao, L., & Niu, J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08101-5 · Cited by 3
“Another meta-analysis, including 3 studies and 178 MS patients, revealed a beneficial effect of prebiotics on mental health, with the proposed mechanism involving the reduction of insulin resistance, inflammation, and oxidative stress [68].”
InfluentialKhalifa, A. Y. Z., Ibrahim, H.-I. M., Sheikh, A., & Khalil, H. E. (2023) · Medicina · doi:10.3390/medicina59101731 · Cited by 3
Immunostimulatory Role of Prebiotics and Probiotics
Mohanty, T., Gurjar, B. P., Yangala, S. B., & Nagarajan, U. (2022) · Wiley eBooks · doi:10.1002/9781394167227.ch7 · Cited by 2
Nutraceuticals in Inflammatory Autoimmune Diseases
Annamma, L. M., Azim, S. A., & Ashmawy, N. S. (2024) · Food bioactive ingredients · doi:10.1007/978-3-031-76481-3_9 · Cited by 1
Kamarei, A. R., Robins, H. F., & Finkelstein, E. A. (2024) · International Journal of Preventive Medicine and Care · doi:10.33140/ijpmc.02.01.04 · Cited by 1
Bioencapsulation for probiotics
Zaidel, D. N. A., Hashim, Z., Muhamad, I. I., Iemsam-arng, J., Dailin, D. J., Manas, N. H. A., Yaakob, H., & Zainol, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91229-7.00003-9
Aznar, M. D. G., Villanueva Guerrero, M. D., Cordero-Ramos, J., Eichau Madueño, S., Bravo, M. M., Ruiz, R. L., & García, M. B. (2022) · Figshare · doi:10.6084/m9.figshare.21376285
Kudiersky, N., Barker, L. A., Dalton, C. F., Sharrack, B., Nair, K. S., Kesterton, S., & Carter, A. (2026) · Research Square · doi:10.21203/rs.3.rs-8086671/v1
Chiou, Y., Chiu, T.-Y., & Chen, M.-J. (2026) · Nutrients · doi:10.3390/nu18071107
“This pathway-level rationale is consistent with randomized trials and evidence syntheses in MS showing favorable shifts in inflammatory markers after probiotic supplementation, supporting hs-CRP as a responsive systemic readout when baseline gut-driven inflammation is present [66].”
Complementary therapies for multiple sclerosis: Scoping review with evidence gap map
López‐Alcalde, J., Yan, Y., Canella, C., Barth, J., Steinemann, N., von Wyl, V., Baum, C., Bolt, S., Haegele-Link, S., Rettenmund, G., et al. (2026) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2026.107243
“…et al., 2014; Guerrero et al., 2022; Gusev et al., 2008; Hanaei et al., 2021; Hansen et al., 2023; Hupperts et al., 2019; Jagannath et al., 2018; Jiang et al., 2021; Kleiner et al., 2023; Langford et al., 2013; Markov ` a et al., 2019; Marx et al., 2020; McLaughlin et al., 2018; Mirashrafi et…”
InfluentialBlanca-Serrano, T., Agredano-Sanchez, M., Gigosos, R. M. L., Navarro, M. F. J., González-Domenech, C. M., & Gutiérrez‐Bedmar, M. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106747
Viana, M. D. M., Pereira, D. D., Santos, S. S., Calderari, M. L. C., da da Silva, V. E. F., Lins, M. P., & Silva, L. H. A. C. (2026) · Antioxidants · doi:10.3390/antiox15101288
“…attenuation of systemic inflammation in MS. Meta-analyses have reported improvements in selected oxidative stress and inflammatory biomarkers following probiotic supplementation in MS; however, the limited and heterogeneous evidence remains inconsistent and precludes robust conclusions [107,108].”
Gut microbiota in multiple sclerosis: immunological mechanisms and therapeutic implications
Niedziela, M., Maruszak, M., Wyżykowska, A., Grygorowicz, J., Faria, G., Mykhalevych, A., Sas-Wyżykowska, M., Blachucik, A., & Kryshtofik, A. (2026) · Aktualności Neurologiczne · doi:10.15557/an.2026.0008
Metadata
- Authors
- Jiang, J., Chu, C., Wu, C., Wang, C., Zhang, C., Li, T., Zhai, Q., Yu, L., Tian, F., & Chen, W.
- Affiliations
- Jiangnan University (CN)
- Nanjing Forestry University (CN)
- Corresponding author
- Yu, Leilei
- Tian, Fengwei
- ORCID
- Venue
- Food & Function
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2021
- Volume
- 12
- Issue
- 6
- Pages
- 2354-2377
- ISSN
- 2042-6496 (ISSN-L)
- 2042-650X
- OpenAlex
- W3128017280
- Cited by
- 52
- References
- 95
- Citations by year
- 2026: 8 · 2025: 4 · 2024: 9 · 2023: 16 · 2022: 11 · 2021: 3
- FWCI
- 1.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Food & Function (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (U1903205, 31772090, 31820103010, 32001665)
- Xinjiang Production and Construction Corps (2018AB010)
- Natural Science Foundation of Jiangsu Province (BK20180603)
- Collaborative Innovationcenter of Food Safety and Quality Control in Jiangsu Province
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, multiple sclerosis, gut microbiota, insulin resistance, oxidative stress, inflammatory markers, motor impairment, disease progression, immunomodulation, preclinical research, randomized controlled trials
- MeSH terms
- Adult, Animals, Female, Humans, Inflammation, Male, Mental Health, Middle Aged, Multiple Sclerosis, Randomized Controlled Trials as Topic, Probiotics, Mice, Rats, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.